Dose Range Study of Anamorelin in Patients With Non-small Cell Lung Cancer
NCT ID: NCT00622193
Last Updated: 2017-04-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
228 participants
INTERVENTIONAL
2008-03-31
2009-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Anlotinib Combined With Nivolumab for Non-Small Cell Lung Cancer
NCT04211896
A Study of BMS-663513 in Combination With Chemoradiation in Subjects With Non Small Cell Lung Carcinoma (NSCLC)
NCT00461110
A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT03743064
A Efficacy and Safety Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung Cancer
NCT04439890
Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Advanced Non-Small Cell Lung Cancer
NCT00193453
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1 Active 50 mg
anamorelin HCl
50 mg tablet
2 Active 100 mg
anamorelin HCl
100 mg tablet
3 Placebo
placebo
placebo tablet
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
anamorelin HCl
50 mg tablet
anamorelin HCl
100 mg tablet
placebo
placebo tablet
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* eligible for treatment of NSCLC with paclitaxel and carboplatin +/- bevacizumab
Exclusion Criteria
* significant obesity, BMI \> 30
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Helsinn Therapeutics (U.S.), Inc
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jennifer Temel, MD
Role: STUDY_DIRECTOR
Massachusetts General Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
Osler Medical
Melbourne, Florida, United States
Augusta Oncology Associates
Augusta, Georgia, United States
South Georgia Medical Center
Valdosta, Georgia, United States
Investigative Clinical Research of Indiana
Indianapolis, Indiana, United States
John Hopkins University
Baltimore, Maryland, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Dana Farber Cancer Center
Boston, Massachusetts, United States
Caritas St. Elizabeth's Medical Center
Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
The West Clinic
Corinth, Mississippi, United States
The West Clinic
Southaven, Mississippi, United States
Washington University School of Medicine
St Louis, Missouri, United States
Duke University Medical Center
Durham, North Carolina, United States
South Carolina Cancer Specialists
Hilton Head Island, South Carolina, United States
The West Clinic
Memphis, Tennessee, United States
Baylor College of Medicine/VAMC
Houston, Texas, United States
The Methodist Hospital Research Institute
Houston, Texas, United States
North West Medical Specialties, PLLC
Puyallup, Washington, United States
Regional Cancer Centre Indira Gandhi Institute of Medical Sciences
Patna, Bihar, India
Cancer Clinic 208
Nagpur, Maharashtra, India
Noble Hospital
Pune, Maharashtra, India
Ruby Hall Clinic
Pune, Maharashtra, India
Kaushalya Medical Foundation Trust Hospital
Thāne, Maharashtra, India
SEAROC Cancer Center
Jaipur, Rajasthan, India
Jawaharlal Nehru Cancer Hospital and Research Centre
Bhopal, , India
Kamakshi Memorial Hospital
Chennai, , India
Dharamshila Cancer Hospital and Research Center
Delhi, , India
Bhagwan Mahaveer Cancer Hospital and Resaerch Center
Jaipur, , India
Birla Cancer Centre SMS Medical College Hospital
Jaipur, , India
Kodlikeri Memorial Hospital
Maharashtra, , India
Jaslok Hospital and Research Centre
Mumbai, , India
Shatabdi Super Speciality Hospital
Mumbai Naka, Nasik, , India
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ST-ANAM-207
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.